AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31615016 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2855 (2855 mg as PGE)
Number of subjects: 108
Study 31615016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 27427434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental simulation alone
Number of subjects: 267
Study 27427434 — intervention group
Group type: EXPERIMENTAL
Intervention: Action planning alone
Number of subjects: 267
Study 27427434 — intervention group
Group type: COMPARATOR
Intervention: Mental simulation and action planning strategies
Number of subjects: 267
Study 25361650 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D imaging system
Number of subjects: 122
Study 25361650 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging system
Number of subjects: 122
Study 23222034 — intervention group
Group type: EXPERIMENTAL
Intervention: stepped combined care management, psychopharmacology, and cognitive behavioral psychotherapy intervention (n = 104)
Number of subjects: 207
Study 23222034 — intervention group
Group type: COMPARATOR
Intervention: usual care control (n = 103)
Number of subjects: 207
Study 21218311 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief personalized motivational interventions
Number of subjects: 497
Study 21218311 — intervention group
Group type: COMPARATOR
Intervention: Information and advice
Number of subjects: 497
Study 18155052 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus and sciatic nerve blocks (CPNB) with ropivacaine 0.2% for 48 hours
Number of subjects: 12
Study 18155052 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 12
Study 17090995 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fluid intake measurement (1,035 ml average, SD=359 ml, range 210 ml to 2,050 ml)
Number of subjects: 111
Study 17090995 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's perceived barriers assessment
Number of subjects: 111
Study 12910836 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular approach with GDC‐10 coils
Number of subjects: 60
Study 12910836 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 60
Study 10883747 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (180 microg four times daily for 7 days)
Number of subjects: 10
Study 9008448 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tissue plasminogen activator (TNK-TPA) administered as a single bolus over 5 to 10 seconds with doses ranging from 5 to 50 mg
Number of subjects: 113
Study 9008448 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tissue plasminogen activator (TNK-TPA)
Number of subjects: 113
Study 8237804 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized burst pacing
Number of subjects: 21
Study 8237804 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized autodecremental (ramp) pacing
Number of subjects: 21
Study 8237804 — intervention group
Group type: COMPARATOR
Intervention: Control group (induced episodes)
Number of subjects: 21
Study 4025160 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker therapy (verapamil or nifedipine)
Number of subjects: 26
Study 29722846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (2 oral doses of 200,000 IU at 2 and 4 weeks)
Number of subjects: 194
Study 29722846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3
Number of subjects: 194
Study 26769248 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner‐led integrated diabetes care innovation
Number of subjects: 12
Study 25675564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparrow-pecking moxibustion
Number of subjects: 90
Study 25675564 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study 23935398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (10.27 ± 4.13 mg/day)
Number of subjects: 365
Study 23935398 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (4.87 ± 2.08 mg/day)
Number of subjects: 365
Study 23935398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine and Amlodipine
Number of subjects: 365
Study 20868317 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed exercise program provided by a qualified exercise professional, updated every 3 weeks for 12 weeks
Number of subjects: 24
Study 20868317 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained current lifestyle habits for 12 weeks
Number of subjects: 24
Study 17983434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (OXY‐TDS) 3.9 mg/day
Number of subjects: 369
Study 15725084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose melphalan-prednisone (MP)
Number of subjects: 272
Study 12937332 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Skill-Building Program (5 home contacts and 1 telephone contact by occupational therapists)
Number of subjects: 255
Study 12937332 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 255
Study 10733537 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP score
Number of subjects: 196
Study 10733537 — intervention group
Group type: COMPARATOR
Intervention: Okuda staging system
Number of subjects: 196
Study 9161271 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond System
Number of subjects: 420
Study 9161271 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 420
Study 9161271 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Bayer System 1
Number of subjects: 420
Study 9161271 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Bayer System 2
Number of subjects: 420
Study 1382323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (3000 ng infused into the graft)
Number of subjects: 0
Study 1382323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4052143 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (3 X 100 mg on the previous day and 100 mg before the test)
Number of subjects: 12
Study 4052143 — intervention group
Group type: COMPARATOR
Intervention: Chlorphenoxamine (80 mg daily dose on the preceding day and 20 mg 1 h before test)
Number of subjects: 12
Study 4052143 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg perorally 2 days before and 5 mg perorally on the preceding day)
Number of subjects: 12
Study 4052143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29265699 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green administration 15 hours before surgery
Number of subjects: 72
Study 29265699 — intervention group
Group type: COMPARATOR
Intervention: Indocyanine green administration at 3, 6, 9, 12, 15, 18, and 24 hours before surgery
Number of subjects: 72
Study 26249333 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention programs
Number of subjects: 41
Study 26249333 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies for obesity prevention programs
Number of subjects: 41
Study 24552831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14236
Study 24552831 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14236
Study 22339102 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (AL-TENS) at Hegu (LI4) and Sanyinjiao (SP6) points, applied twice weekly for 8 weeks.
Number of subjects: 66
Study 22339102 — intervention group
Group type: COMPARATOR
Intervention: AL-TENS on nonacupoints (Control group).
Number of subjects: 66
Study 20166313 — intervention group
Group type: EXPERIMENTAL
Intervention: Short release time
Number of subjects: 24
Study 20166313 — intervention group
Group type: EXPERIMENTAL
Intervention: Long release time
Number of subjects: 24
Study 18727133 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health services in primary care
Number of subjects: 2022
Study 18727133 — intervention group
Group type: COMPARATOR
Intervention: Referral to community-based services (Control)
Number of subjects: 2022
Study 16207547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (group P)
Number of subjects: 34
Study 16207547 — intervention group
Group type: COMPARATOR
Intervention: Non-pravastatin (group NP)
Number of subjects: 34
Study 12371079 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐Thyroxin Henning 100
Number of subjects: 60
Study 12371079 — intervention group
Group type: COMPARATOR
Intervention: Eferox 100
Number of subjects: 60
Study 11064964 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based parent education programs
Number of subjects: 16
Study 11064964 — intervention group
Group type: COMPARATOR
Intervention: Waiting list, no-treatment or placebo control group
Number of subjects: 16
Study 9350101 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g)
Number of subjects: 60
Study 9350101 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha gel (2 x 10(6) IU/g)
Number of subjects: 60
Study 9350101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8457025 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline CR 10 mg twice daily
Number of subjects: 21
Study 8457025 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 40 micrograms four times daily
Number of subjects: 21
Study 8457025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terbutaline CR and ipratropium
Number of subjects: 21
Study 3092392 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide and metformin
Number of subjects: 68
Study 3092392 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 68
Study 3092392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no insulin treatment)
Number of subjects: 68
Study 29700925 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctal plug
Number of subjects: 48
Study 27107842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet without fish or meat
Number of subjects: 74
Study 27107842 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric conventional antidiabetic diet
Number of subjects: 74
Study 27107842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 74
Study 24643104 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (Group 1)
Number of subjects: 30
Study 24643104 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia (Group 2)
Number of subjects: 30
Study 22572600 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC)
Number of subjects: 50
Study 22572600 — intervention group
Group type: COMPARATOR
Intervention: Radioopaque markers (ROM)
Number of subjects: 50
Study 22572600 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC) and Radioopaque markers (ROM)
Number of subjects: 50
Study 20533132 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal mesh rectopexy with sterile talc-soaked mesh
Number of subjects: 120
Study 20533132 — intervention group
Group type: COMPARATOR
Intervention: Abdominal posterior mesh rectopexy
Number of subjects: 120
Study 18664538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lipid/heparin infusion
Number of subjects: 12
Study 18664538 — intervention group
Group type: COMPARATOR
Intervention: saline/heparin infusion
Number of subjects: 12
Study 15836682 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally directed epidural catheter (IUEC, n = 40)
Number of subjects: 75
Study 15836682 — intervention group
Group type: COMPARATOR
Intervention: Classic midline catheter (CMEC, n = 35)
Number of subjects: 75
Study 15836682 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally directed epidural catheter (IUEC)
Number of subjects: 75
Study 15836682 — intervention group
Group type: COMPARATOR
Intervention: Classic midline catheter (CMEC)
Number of subjects: 75
Study 12208800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast 450 mg BID for 3 months
Number of subjects: 11484
Study 12208800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast (300 and 450 mg BID for 1 or 3 months)
Number of subjects: 11484
Study 12208800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11484
Study 10335729 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural teaching sites
Number of subjects: 294
Study 10335729 — intervention group
Group type: COMPARATOR
Intervention: Urban and suburban teaching sites
Number of subjects: 294
Study 10335729 — intervention group
Group type: COMPARATOR
Intervention: Primary care specialty (family medicine, medicine, pediatrics, joint medicine and pediatrics)
Number of subjects: 294
Study 10335729 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic location of the site
Number of subjects: 294
Study 10335729 — intervention group
Group type: COMPARATOR
Intervention: Primary care specialty and geographic location
Number of subjects: 294
Study 8999380 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser CO2 and intramuscular beta‐interferon
Number of subjects: 230
Study 8999380 — intervention group
Group type: COMPARATOR
Intervention: Laser CO2
Number of subjects: 230
Study 1958451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily with ranitidine 300 mg twice daily
Number of subjects: 18
Study 1958451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily with cimetidine 800 mg daily
Number of subjects: 18
Study 1958451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31789723 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term medical therapy (up to 10 years)
Number of subjects: 0
Study 31789723 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine ablation (RAI) with higher weight-based doses of I-131 (250 μCI/g thyroid tissue)
Number of subjects: 0
Study 31789723 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal or neonatal TSH receptor antibodies and TSH at 3-7 days of age
Number of subjects: 0
Study 31789723 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term medical therapy beyond two years
Number of subjects: 0
Study 31789723 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine ablation (RAI)
Number of subjects: 0
Study 31675546 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated MET/PE (n=95)
Number of subjects: 183
Study 31675546 — intervention group
Group type: COMPARATOR
Intervention: Phased MET/PE (n=88)
Number of subjects: 183
Study 28650680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 28650680 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride, 5 mg per day for 4 weeks
Number of subjects: 450
Study 28650680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride, 0.5 mg per day for 4 weeks
Number of subjects: 450
Study 25037034 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent influenza vaccine (ATIV)
Number of subjects: 0
Study 25037034 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted trivalent influenza vaccine (TIV)
Number of subjects: 0
Study 24057811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin + Dexamethasone
Number of subjects: 60
Study 24057811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin + Placebo
Number of subjects: 60
Study 24057811 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 60
Study 21187264 — intervention group
Group type: EXPERIMENTAL
Intervention: High educational level
Number of subjects: 553
Study 21187264 — intervention group
Group type: COMPARATOR
Intervention: Low educational level
Number of subjects: 553
Study 19936182 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel of 13-20 cmH(2)O
Number of subjects: 20
Study 19936182 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel of 8-15 cmH(2)O
Number of subjects: 20
Study 16904951 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional communication strategy
Number of subjects: 167
Study 16904951 — intervention group
Group type: COMPARATOR
Intervention: Usual communication strategy
Number of subjects: 167
Study 14748901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering drug treatment
Number of subjects: 0
Study 11915781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (200 mg of ascorbic acid twice a day)
Number of subjects: 16
Study 11915781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 mg of lactose)
Number of subjects: 16
Study 11915781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 16
Study 9549449 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education at birth and three months later (group A)
Number of subjects: 540
Study 9549449 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education at birth only (group B)
Number of subjects: 540
Study 9549449 — intervention group
Group type: COMPARATOR
Intervention: No health education at birth (group C)
Number of subjects: 540
Study 9549449 — intervention group
Group type: COMPARATOR
Intervention: No health education (group D)
Number of subjects: 540
Study 8307445 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (15 mg orally thrice daily)
Number of subjects: 12
Study 2661242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release naproxen (1 g daily)
Number of subjects: 0
Study 2661242 — intervention group
Group type: COMPARATOR
Intervention: Conventional naproxen capsules (500 mg twice daily)
Number of subjects: 0
Study 1101907 — intervention group
Group type: EXPERIMENTAL
Intervention: Niflumic acid
Number of subjects: 0
Study 1101907 — intervention group
Group type: COMPARATOR
Intervention: Aloxiprin
Number of subjects: 0
Study 31025449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Frail Multicomponent Training Intervention (16-week training protocol, 60-min sessions, three alternate days, combining aerobic, muscle strength, flexibility, and balance exercises)
Number of subjects: 0
Study 31025449 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28541500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hyperimmune bovine IgG (bIgG) raised against CFA/I minor pilin subunit (CfaE)
Number of subjects: 31
Study 28541500 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive control (CFA/I fimbraie)
Number of subjects: 31
Study 28541500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25395392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liposomal iron (30 mg/day)
Number of subjects: 99
Study 25395392 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron gluconate (1000 mg total, 125 mg infused weekly)
Number of subjects: 99
Study 25395392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 23571819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12 (daily dose of 10^10 colony-forming units)
Number of subjects: 106
Study 23571819 — intervention group
Group type: COMPARATOR
Intervention: Control group (xylitol or sorbitol tablets)
Number of subjects: 106
Study 24800342 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament, non-absorbable Polypropylene (Prolene) No. 1 suture material (Group-A)
Number of subjects: 274
Study 24800342 — intervention group
Group type: COMPARATOR
Intervention: Polyfilament, absorbable, co-polymer of Polylactide with Polyglycolide (Vicryle) No. 1 (Group-B)
Number of subjects: 274
Study 18995160 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement on a gel pillow (n = 41)
Number of subjects: 81
Study 18995160 — intervention group
Group type: COMPARATOR
Intervention: Usual care on a standard mattress (n = 40)
Number of subjects: 81
Study 16926566 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed practice regimen (weekly)
Number of subjects: 38
Study 16926566 — intervention group
Group type: COMPARATOR
Intervention: Massed practice regimen (1 day)
Number of subjects: 38
Study 14510985 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcal throat infections in psoriasis patients
Number of subjects: 208
Study 14510985 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-haemolytic streptococci culture from psoriasis patients
Number of subjects: 208
Study 14510985 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation of psoriasis after streptococcal isolation
Number of subjects: 208
Study 14510985 — intervention group
Group type: COMPARATOR
Intervention: Control group (household controls)
Number of subjects: 208
Study 10764030 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal specimens tested for pathogens
Number of subjects: 2803
Study 10764030 — intervention group
Group type: EXPERIMENTAL
Intervention: Age comparison between individuals with and without pathogens
Number of subjects: 2803
Study 8761842 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (n = 20)
Number of subjects: 30
Study 8761842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study 8761842 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 30
Study 8761842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8761842 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and Placebo
Number of subjects: 30
Study 1307461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 to 240 mg daily, 3 to 4 tablets a day)
Number of subjects: 87
Study 1307461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 3838352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 0
Study 3838352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30552078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltern als Therapeuten (E@T)
Number of subjects: 66
Study 30552078 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 66
Study 26348685 — intervention group
Group type: EXPERIMENTAL
Intervention: Web group (access to Web-based information)
Number of subjects: 235
Study 26348685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scheduled contact)
Number of subjects: 235
Study 26348685 — intervention group
Group type: COMPARATOR
Intervention: Phone group (2 scheduled phone contacts)
Number of subjects: 235